Modality
Nanobody
MOA
IL-13i
Target
LAG-3
Pathway
RNA Splicing
Fabry
Development Pipeline
Preclinical
~Jan 2022
→ ~Apr 2023
Phase 1
~Jul 2023
→ ~Oct 2024
Phase 2
Jan 2025
→ Jun 2027
Phase 2Current
NCT03484162
454 pts·Fabry
2025-01→2027-06·Completed
454 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-10-126mo awayAdCom· Fabry
2027-06-261.2y awayPh2 Data· Fabry
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2
Complet…
Catalysts
AdCom
2026-10-12 · 6mo away
Fabry
Ph2 Data
2027-06-26 · 1.2y away
Fabry
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03484162 | Phase 2 | Fabry | Completed | 454 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| ALN-6288 | Alnylam | Approved | LAG-3 |